US Approval Of Vabomere Could Help Alleviate TMC's Financial Troubles
The antibiotic Vabomere demonstrated statistical superiority over Zosyn, and could be a more attractive option than existing treatments for complicated urinary tract infections.
You may also be interested in...
Repeat antibiotic entrepreneurs raised $33m to launch Qpex with assets from The Medicines Co. Also, Taiho increases VC fund to $300m and TP Therapeutics raises $80m.
Products in the final stages of pre-marketing evaluation at the European Medicines Agency include drugs for influenza, NSCLC, aTTP and HIV infection.
CEO Daniel Wechsler talked with Scrip about being a pure-play specialist in the challenging antibiotics market, following the acquisition of The Medicines Co.'s anti-infectives franchise and a reverse merger with Cempra last year.